The endocannabinoid system: a new perspective for cardiometabolic risk control.
Francischetti
Emilio Antonio
EA
Hypertension Clinic, Laboratory of Clinical and Experimental Pathophysiology, Rio de Janeiro State University, Rio de Janeiro, RJ, Brazil. eafranc@uerj.br
de Abreu
Virginia Genelhu
VG
D063387:Cannabinoid Receptor Antagonists; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism / Q000502:physiology*; D002186:Cannabinoids / Q000494:pharmacology / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000378:metabolism* / Q000517:prevention & control; D002986:Clinical Trials as Topic; D063388:Endocannabinoids; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects; D012307:Risk Factors
D063387:Cannabinoid Receptor Antagonists; D063385:Cannabinoid Receptor Modulators; D002186:Cannabinoids; D063388:Endocannabinoids